Rapid In Vivo Antibody Discovery

Accelerating Biotherapeutics with Innovation

The BinderGenᵀᴹ Platform

De Novo Monoclonal Antibody Discovery at Unprecedented Speed

In 6 weeks, Immunovive’s In vivo BinderGenᵀᴹ platform delivers:

·       Diverse panel of target-specific affinity-ranked monoclonal antibodies

·       Natively paired VH/VL sequences

·       Subnanomolar affinity or better

·       Broad repertoire diversity

·       >70% reduction in discovery timelines

·       Validated in virtually all rodent systems including humanized, knockouts, conditional, inducible, and transgenics.

Our Mission

Our mission is to accelerate the discovery and development of immunotherapeutics. Our BinderGenᵀᴹ lead discovery platform generates diverse in vivo-matured monoclonal antibody target binders in 6 weeks built to empower downstream preclinical drug development processes including target validation, proof-of-concept, lead identification and optimization, critical reagents, diagnostics, and provide high-quality substrate for multimodality engineering and AI/ML datasets.

Our Team

Devin E. Turner, Ph.D.
Founder and CEO

Devin Turner

Devin E. Turner, Ph.D., Founder and CEO

Devin Turner is the founder of Abveris and the creator of DiversimAbTM technology, an antibody discovery platform that addresses an unmet need in biotherapeutics. In over 20 years of experience, Devin has successfully helped hundreds of drug hunters in over 1,500+ antibody discovery campaigns of virtually all possible target types. In six years without investment, Devin led Abveris through substantial growth, technological innovation, a successful exit and fulfilling its mission to deliver biotherapeutic lead molecules to drug hunters worldwide. More recently, Devin was the Head of Antibody Discovery Services at Alloy Therapeutics, where he led a world-class multidisciplinary team creating fully human antibody-based therapeutics and their first IND-filing. Devin continues his passion for immunotherapeutics through his latest company, Immunovive, a Boston-based antibody discovery services company that is accelerating biologics discovery and development via its proprietary in vivo-based antibody hit generation platform, BinderGenTM, delivering diverse panels of high affinity monoclonal hybridomas in unprecedented timelines. Prior to industry, Devin authored several genetically-modified in vivo and in vitro systems that have since been distributed globally and have served as cornerstone biotools in cancer research. When not voluntarily immersed in immunology, Devin enjoys BBQing, hiking, fishing, biking, boating, and being the best dad possible. Devin earned his B.S. in Molecular, Cellular, and Developmental Biology from UCLA and his Ph.D. in Immunology from Harvard Medical School.

Rashed Abdullah, Ph.D., PMP
Associate Director of Operations and Business Development

Rashed Abdullah

Rashed Abdullah, Ph.D., PMP, Associate Director of Operations and Business Development

Dr. Rashed Abdullah is a seasoned scientist with over two decades of experience in therapeutic antibody discovery, oncology, vaccine development, and neurodegenerative disease research. A certified Project Management Professional (PMP), he has led R&D programs and cross-functional teams across biotech and CRO environments. His expertise spans monoclonal and polyclonal antibody development, AOC/ADC platforms, assay design, and preclinical strategy. Dr. Abdullah has held leadership roles at Gennao Bio, Abveris (now Twist Bio), and Immunovive LLC, where he currently serves as Associate Director of Operations and Business Development. He holds a Ph.D. in Biology from St. John's University and has contributed to numerous peer-reviewed publications in the field of therapeutic discovery.

Tom Daly, Jr.

Tom Daly, Jr., M.Sc., Scientist

Tom has over 17 years combined experience in drug discovery, particularly using in vivo models in disease areas of cancer and autoimmune diseases. Throughout his career he has dedicated his efforts to discover and develop drug therapies such as Necuparanib, which reached Phase II; CTX-471, currently in Phase I clinical trials; and others that are still in preclinical stage development. He was also on the initial development team for Nipoclamib, an anti-FcRn approved by the FDA in April 2025. Tom has developed tumor, platelet depletion, and rescue in vivo models, as well as other pharmacokinetic models. Most recently at Alloy Therapeutics and now here at Immunovive, he has specialized in the generation of monoclonal hybridoma colonies from mouse B cells that generate target specific antibodies for customer projects and is dedicated to the delivery of a potential drug target for clients. He earned his Masters Degree in Biotechnology from Worcester State University.

Contact Us

Accelerate Your Discovery!

Contact Devin Directly

devin@immunovivellc.com